Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Arun T, Petheram K, Tallantyre E, Ford H, Chataway J, Dougall NM, Doshi A, Englezou C, Farrell R, Hughes S, McDonnell G, Murray K, Rees R, Robertson N, Schmierer K, Dobson R; Association of British Neurologists, Special interest group for MS and neuroinflammation. Arun T, et al. Among authors: chataway j. Mult Scler Relat Disord. 2024 Dec;92:106144. doi: 10.1016/j.msard.2024.106144. Epub 2024 Nov 10. Mult Scler Relat Disord. 2024. PMID: 39579643
Associations between fatigue impact and physical and neurobehavioural factors: An exploration in people with progressive multiple sclerosis.
Connolly L, Chatfield S, Freeman J, Salter A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, DeLuca J, Dalgas U, Farrell R, Feys P, Filippi M, Inglese M, Meza C, Moore NB, Motl RW, Rocca MA, Sandroff BM, Feinstein A. Connolly L, et al. Among authors: chataway j. Mult Scler Relat Disord. 2024 Oct;90:105798. doi: 10.1016/j.msard.2024.105798. Epub 2024 Aug 9. Mult Scler Relat Disord. 2024. PMID: 39213864 Free article.
Heterogeneity of aerobic fitness changes with exercise training in progressive multiple sclerosis: Secondary, exploratory analysis of data from the CogEx trial.
Motl RW, Sandroff BM, Hernandez RS, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Rocca MA, Salter A, Feinstein A; CogEx Research Team. Motl RW, et al. Among authors: chataway j. Mult Scler J Exp Transl Clin. 2024 Dec 5;10(4):20552173241301030. doi: 10.1177/20552173241301030. eCollection 2024 Oct-Dec. Mult Scler J Exp Transl Clin. 2024. PMID: 39651332 Free PMC article.
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network. Connick P, et al. Among authors: chataway j. BMJ Open. 2018 Aug 30;8(8):e021944. doi: 10.1136/bmjopen-2018-021944. BMJ Open. 2018. PMID: 30166303 Free PMC article. Clinical Trial.
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial.
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC, Chowdhury F, Stutters J, Ricciardi A, Prados F, MacManus D, Grussu F, Karsa A, Samson B, Battiston M, Gandini Wheeler-Kingshott CAM, Shmueli K, Ciccarelli O, Barkhof F, Chataway J; UCL MS-STAT2 investigators. Williams T, et al. Among authors: chataway j. Neuroimage Rep. 2024 Sep;4(3):100216. doi: 10.1016/j.ynirp.2024.100216. Neuroimage Rep. 2024. PMID: 39328985 Free PMC article.
Prevalence and Associated Clinical Characteristics of Walking-Related Motor, Cognitive, and Fatigability in Progressive Multiple Sclerosis: Baseline Results From the CogEx Study.
Ramari C, D'hooge M, Dalgas U, Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter GR, DeLuca J, Farrell R, Filippi M, Freeman J, Inglese M, Meza C, Motl RW, Rocca MA, Sandroff BM, Salter A, Kos D, Feys P. Ramari C, et al. Among authors: chataway j. Neurorehabil Neural Repair. 2024 May;38(5):327-338. doi: 10.1177/15459683241236161. Epub 2024 Mar 1. Neurorehabil Neural Repair. 2024. PMID: 38426484
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
De Angelis F, Cameron JR, Eshaghi A, Parker R, Connick P, Stutters J, Plantone D, Doshi A, John N, Williams T, Calvi A, MacManus D, Barkhof F, Chandran S, Weir CJ, Toosy A, Chataway J; MS-SMART trial investigators. De Angelis F, et al. Among authors: chataway j. J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801. doi: 10.1136/jnnp-2024-334801. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39694820
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis.
John NA, Li Y, De Angelis F, Stutters J, Prados F, Doshi A, Calvi A, Williams T, Plantone D, Phan T, Gandini Wheeler-Kingshott CAM, Barkhof F, Chataway J; MS‐SMART Investigators. John NA, et al. Among authors: chataway j. Eur J Neurol. 2025 Jan;32(1):e16586. doi: 10.1111/ene.16586. Eur J Neurol. 2025. PMID: 39691073 Free PMC article. Clinical Trial.
245 results